Progetto FP7-SME-2012 "A new methodology based on an advanced molecular probe for early detection of DPD enzyme deficiency in oncological patients, also enabling a personalised and effective drug management" (CARESS)

The CARESS Project is a joint effort of 3 research institutions from Italy and France together with 4 SME's (small and medium sized entities) from Austria, France and Italy to develop an accurate, easy-to-use and cost efficient technology for determination of the DPD (dihydropyrimidine dehydrogenase) activity level. The enzyme DPD is of crucial importance in the metabolism and deactivation of 5-FU (fluorouracil), a cytostatic drug most successfully and most commonly used in treatment of breast, colon and skin cancer. In case of a genetically caused DPD deficiency 5-FU therapy will result in severe toxic reactions, which can be even fatal at the very first dose of 5-FU. Thus simple and reliable DPD activity screening is of essential importance for early detection of serious counter-indications for 5-FU therapy.

Sviluppo di una tecnologia per l'analisi rapida e non invasiva dell'attività dell'enzima diidropirimidinadeidrogenasi, DPD, in pazienti da trattare con 5-fluorouracile, un potente chemioterapico, che può risultare fatale in pazienti DPD deficienti. Periodo di partecipazione all'attività: 2013-2015